In Section C, participants will receive ABBV-744 and oral navitoclax. In Segment D, participants will acquire ABBV-744 and ruxolitinib. Contributors will acquire treatment until finally condition progression or even the individuals are not able to tolerate the study drugs. and after that market H3K27Ac at this area. Chromatin hyperacetylation could https://barbarav121nyj5.wiki-racconti.com/user